Lactobacilli and its metabolites as potential probiotics against Gardenerella vaginalis
[Excerpt] Bacterial vaginosis (BV) is the most prevalent vaginal disorder in women of childbearing age, posing some significant health risks, such as abnormal pregnancy, pelvic inflammatory disease and an increased risk of sexual transmitted infections, including HIV [1]. It is characterized by a disruption in the normal balance of bacteria in the vagina with a reduction on lactobacilli number and an overgrowth of anaerobes [2]. Despite several species have been associated with this condition [3], several studies point out for the higher virulence potential of Gardnerella vaginalis [4, 5, 6] and therefore it has been proposed as the main etiological candidate of BV. Current BV treatment is based in antibiotic therapy leading to an increased resistance of BV anaerobes and to a severe reduction of healthy lactobacilli strains in the vaginal epithelium [7, 8, 9]. Therefore, a more appropriate treatment is required, aiming to decrease G. vaginalis and also to promote the lactobacilli re-colonization in BV patients [10]. Previous studies have shown the potential of lactobacilli in preventing vaginal colonization by pathogens [11, 12] through different mechanisms, which may include auto-aggregation, co-aggregation with pathogenic microorganisms, adhesion to epithelial cells and/or by the production of some metabolites (such as lactic acid, hydrogen peroxide, bacteriocins, bacteriocin-like proteins and biosurfactants) [13]. Thus, the probiotic properties of lactobacilli should be explore in order to evaluate their potential as a more effective treatment for BV. [.] ; The authors acknowledge the financial support by European Union funds (FEDER/COMPETE) and by national funds (FCT) under the project with reference FCOMP-01-0124-FEDER008991 (PTDC/BIA-MIC/098228/2008). ...